Report Highlights

South America Necrotising Enterocolitis: Market Overview

The South American necrotising enterocolitis market is structurally bifurcated between a dominant public health system — where government procurement rules define product access — and a smaller but faster-growing private neonatal care sector. Brazil accounts for an estimated 58% of regional market value, driven by the sheer volume of preterm births processed through SUS-funded facilities. Argentina, Colombia, and Chile collectively represent the next tier. Government bodies, not clinicians or procurement managers, are the primary demand architects in this market: ANVISA in Brazil, INVIMA in Colombia, and the ISP in Chile each set the product access framework within which commercial participants must operate.

Private sector leadership is visible primarily in premium diagnostics, human milk fortifiers, and probiotic prophylaxis, where SUS reimbursement does not extend. Companies such as Prolacta Bioscience and Abbott Laboratories operate in this private channel, supplying high-acuity NICUs in São Paulo, Bogotá, and Santiago. However, the structural reality is that public-sector procurement — governed by annual licitação (tender) cycles in Brazil and similar mechanisms in Argentina's PAMI programme — dictates volume. The market's current form reflects two decades of government investment in NICU expansion under programmes like Brazil's Rede Cegonha, which made neonatal intensive care a national public health priority and simultaneously constrained commercial pricing power across all therapeutic categories.

Policy-Driven Growth in the South American NEC Market

Three specific policy mechanisms are driving measurable demand growth across the region. First, Brazil's Rede Cegonha programme, instituted under Portaria MS/GM No. 1.459/2011 and substantially expanded through the Previne Brasil initiative, mandates minimum neonatal care standards in all SUS-accredited maternity hospitals, directly funding NICU equipment procurement, parenteral nutrition supplies, and diagnostic infrastructure. Facilities failing compliance benchmarks face SUS accreditation withdrawal, which creates a non-discretionary demand floor for NEC-related consumables and nutrition products that is independent of hospital budget cycles or clinical discretion.

Second, ANVISA's Resolution RDC No. 171/2006 formalised Brazil's national human milk bank network and mandated pasteurisation and microbiological testing standards, generating sustained procurement of diagnostic testing kits and specialised processing equipment across Rede BLH's 220-plus banks. Third, Colombia's Instituto de Evaluación Tecnológica en Salud (IETS) issued NEC-specific clinical practice guidelines in 2021 under the framework of the Plan de Beneficios en Salud (PBS), creating a reimbursement pathway for probiotic prophylaxis products that meet efficacy thresholds. This guideline-driven reimbursement mechanism translates directly into formulary inclusion for qualifying products and represents the clearest commercial entry point in the Andean sub-region.

Regulatory Barriers and Compliance Costs

Market entry across South America is constrained by fragmented, country-specific regulatory regimes that do not mutually recognise approvals. ANVISA, Brazil's Agência Nacional de Vigilância Sanitária, requires separate registration for medical nutrition products under RDC No. 60/2019, with average approval timelines of 18 to 24 months for novel formulations and registration fees that reach BRL 120,000 for Class III devices. Colombia's INVIMA imposes a parallel registration process under Decree 4725/2005 for medical devices, with approval timelines of 12 to 18 months and a mandatory local technical representative requirement that adds 8 to 12% to annual operating costs for foreign manufacturers without an in-country entity.

Argentina's ANMAT administers product authorisation under Disposición 2318/2002 and its subsequent amendments, but chronic administrative backlogs — exacerbated by economic instability — extend approval timelines beyond 30 months in many cases, effectively excluding time-sensitive product categories. Local content requirements, while not formally legislated for pharmaceutical inputs, are enforced indirectly through SUS tender scoring criteria in Brazil, which award preference points to products with domestic manufacturing or packaging operations. This Compras Governamentais preference framework, administered by the Ministério da Saúde, disadvantages fully imported NEC therapeutics against locally assembled alternatives, even when clinical profiles are equivalent.

Policy-Created Opportunities in South America

Colombia's PBS reform cycle, expected to undergo its next comprehensive revision in 2026 under the stewardship of the Ministerio de Salud y Protección Social, presents the most time-sensitive commercial opportunity in the region. The revision is anticipated to expand NEC-specific reimbursement coverage to include lactoferrin supplementation and targeted probiotic strains, categories currently excluded from mandatory coverage. Manufacturers with IETS-compliant clinical dossiers submitted before the Q2 2026 consultation deadline stand to secure formulary placement ahead of competitor products, as post-revision inclusion requires a separate, slower health technology reassessment process administered by IETS that averages 26 months.

Brazil's ongoing expansion of its Programa Nacional de Triagem Neonatal (PNTN), administered by the Ministério da Saúde under Portaria No. 822/2001 and expanded by Law 14.154/2021, is creating structural demand for advanced point-of-care diagnostics within NICU settings. The 2021 law mandated the addition of new conditions to the national newborn screening panel, requiring upgraded laboratory infrastructure in public maternity hospitals — infrastructure that is directly applicable to NEC biomarker diagnostics. Suppliers of bedside inflammatory marker testing platforms and near-patient imaging systems have a direct procurement pathway through SUS capital equipment budgets, which are ring-fenced separately from operational pharmaceutical budgets and therefore less subject to the pricing pressures that constrain consumable margins.

Market at a Glance

Leading Market Participants

• Abbott Laboratories
• Mead Johnson Nutrition (Reckitt)
• Prolacta Bioscience
• Pfizer
• Danone Nutricia
• Nestlé Health Science
• Chr. Hansen
• Fresenius Kabi
• Baxter International
• B. Braun Melsungen

Regulatory and Policy Environment

The primary legislative framework governing NEC-related products in South America's largest market is Brazil's Lei No. 9.782/1999, which established ANVISA and defined its authority over food, drug, and medical device regulation. For nutritional therapeutics used in NEC management, the operative instrument is RDC No. 60/2019, which classifies enteral nutrition formulas and human milk fortifiers under a risk-based tier system with differentiated registration fees, dossier requirements, and post-market surveillance obligations. ANVISA's Gerência de Alimentos (GIALI) administers these registrations, and its 2023 inspection programme identified labelling non-compliance in 34% of imported enteral nutrition products assessed — signalling heightened enforcement risk for foreign suppliers operating through distributors without dedicated regulatory staff. Upcoming ANVISA resolution updates, anticipated in 2026, are expected to impose stricter clinical evidence requirements for probiotic health claims in neonatal products, directly affecting product positioning strategies.

Compared to regional peers, Brazil's framework is the most mature and most demanding. Colombia's INVIMA system is broadly comparable in structure but operates with greater procedural flexibility and a faster-track pathway for products already registered in INVIMA-recognised reference countries including the United States and European Union members. Chile's ISP, operating under Decreto No. 3/2010, offers the shortest registration timelines in the region — averaging 9 to 12 months — and has a mutual recognition agreement with PAHO that facilitates expedited review for WHO-prequalified products. Argentina's ANMAT remains the most unpredictable jurisdiction, with regulatory timelines subject to government budget cycles and, since 2022, a mandatory dollarisation of registration fees that has increased effective entry costs for foreign manufacturers by an estimated 40%.

Long-Term Policy Outlook for South American NEC Care

By 2032, the most significant policy shift reshaping this market will be the anticipated adoption of universal NICU quality standards across Mercosur member states, currently being developed under the Mercosur Salud framework with technical support from PAHO. Draft harmonisation protocols circulated in 2024 propose common minimum standards for NICU staffing ratios, parenteral nutrition protocols, and NEC prophylaxis guidelines — standards that, once adopted, will create a de facto regional formulary for core NEC-related products. This harmonisation removes the current regulatory arbitrage that incentivises manufacturers to prioritise Chile or Colombia over Brazil, and will raise the compliance baseline across Argentina, Uruguay, and Paraguay, which currently operate below the proposed Mercosur minimum thresholds.

Brazil's Ministério da Saúde has separately signalled, through its 2023–2027 Plano Plurianual, an intent to increase domestic production of specialised medical nutrition products under the Complexo Econômico-Industrial da Saúde (CEIS) strategy, which incentivises public-private partnerships for strategic health input manufacturing. By 2028, CEIS-supported domestic manufacturers of human milk fortifiers and parenteral amino acid solutions are projected to achieve scale sufficient to compete in SUS tenders, which will structurally disadvantage imported products that currently hold preferred supplier status in the absence of domestic alternatives. Foreign manufacturers that do not establish local manufacturing or co-production agreements with Brazilian partners before 2027 face progressive margin erosion as CEIS-backed competitors enter the public procurement channel with price advantages of 25 to 35%.